RhumbLine Advisers’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-59,331
| Closed | -$10.7M | – | 2897 |
|
|
2017
Q3 | $10.7M | Buy |
59,331
+3,771
| +7% | +$525K | 0.02% | 640 |
|
|
2017
Q2 | $5.76M | Buy |
55,560
+8,466
| +18% | +$691K | 0.01% | 921 |
|
|
2017
Q1 | $3.7M | Buy |
47,094
+2,375
| +5% | +$147K | 0.01% | 1195 |
|
|
2016
Q4 | $2M | Buy |
44,719
+2,780
| +7% | +$136K | 0.01% | 1452 |
|
|
2016
Q3 | $2.34M | Buy |
41,939
+2,991
| +8% | +$167K | 0.01% | 1302 |
|
|
2016
Q2 | $1.95M | Buy |
38,948
+6,365
| +20% | +$313K | 0.01% | 1363 |
|
|
2016
Q1 | $1.5M | Buy |
32,583
+3,815
| +13% | +$185K | ﹤0.01% | 1561 |
|
|
2015
Q4 | $1.77M | Buy |
28,768
+2,660
| +10% | +$187K | 0.01% | 1436 |
|
|
2015
Q3 | $1.45M | Buy |
26,108
+993
| +4% | +$62.5K | ﹤0.01% | 1539 |
|
|
2015
Q2 | $1.53M | Buy |
25,115
+15,655
| +165% | +$893K | ﹤0.01% | 1597 |
|
|
2015
Q1 | $546K | Buy |
9,460
+2,525
| +36% | +$169K | ﹤0.01% | 2253 |
|
|
2014
Q4 | $400K | Buy |
+6,935
| New | +$292K | ﹤0.01% | 2408 |
|
RhumbLine Advisers's KITE Position: Q4 2017 in Review
RhumbLine Advisers sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 59,331 shares — an estimated $10.7M sold.
RhumbLine Advisers first reported a position in KITE in Q4 2014 and held it in 12 quarters. The position peaked at $10.7M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- RhumbLine Advisers reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- RhumbLine Advisers sold 59,331 Kite Pharma, Inc. shares in Q4 2017, an estimated $10.7M.
- RhumbLine Advisers first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 12 quarters.
- RhumbLine Advisers's Kite Pharma, Inc. position peaked at $10.7M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on RhumbLine Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.